The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy ...

The biotech engaged with the FDA on alternative pathways to approval after seeing safety and efficacy data from the phase 1/2 ...

Sangamo's phase 1/2 STARR study data using isaralgagene civaparvovec targeting patients with Fabry Disease is expected in H1 2025. Learn more on SGMO stock here.

Shares in Sangamo Therapeutics (Nasdaq: SGMO) surged around 40% on Tuesday, following the announcement that the US Food and ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares are moving higher Tuesday after the company announced the FDA approved an ...

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) and keeping the ...

Sangamo (SGMO) announced the outcome of a recent interaction with the FDA, providing a clear regulatory pathway to accelerated approval for ...

There has been a gene therapy on the market for people with the bleeding disorder haemophilia A since 2022, but take-up has been very slow. Pfizer and Sangamo are hoping for a faster trajectory ...

Pfizer and Sangamo have restarted recruitment of patients into their registration trial for haemophilia A gene therapy giroctocogene fitelparvovec, after the FDA lifted a clinical hold on the study.

Sangamo operates in the highly competitive gene therapy space, where numerous companies are vying for market share and investment. The company's partnerships with industry leaders like Genentech ...

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 ...

This development could result in up to $220 million in milestone payments and royalties between 14-20% for Sangamo. The company is actively seeking collaborations for isaralgagene civaparvovec (ST-920 ...